Injectable “cocktail” hydrogel with dual‐stimuli‐responsive drug release, photothermal ablation, and drug‐antibody synergistic effect
Abstract The combination of the first‐line standard chemotherapeutic drug doxorubicin hydrochloride (DOX) and the molecular‐targeted drug Herceptin (HCT) has emerged as a promising strategy for human epidermal growth receptor 2 (HER‐2) overexpressing breast cancer treatment. However, insufficient dr...
| मुख्य लेखकों: | , , , , , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
Wiley
2024-04-01
|
| श्रृंखला: | SmartMat |
| विषय: | |
| ऑनलाइन पहुंच: | https://doi.org/10.1002/smm2.1148 |